Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: Transcranial Magnetic Stimulation and transcranial direct current stimulation: TMS INTERVENTION:
1. Continuous theta burst stimulation TMS OVER left TPJ at 120 percent of RMT. 600 pulse
cathode over left TPJ and anode over left DLPFC. 2mA of current with 20 seconds fade in fade out phase- will be delivered for 20 minutes.
2. 2 sessions will be delivered 3 hours apart.
3. Correspond
Sponsors
DBT/Wellcome Trust India Alliance (India Alliance)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Schizophrenia Diagnosis according to the DSM-5 2. Age 18-45 years; 3. Any sex; 4. Right-Handedness using Edinburgh Handedness Inventory 5. Persistence of auditory hallucinations without remission despite treatment with at least one antipsychotic medication at an adequate dose for a minimum duration of six weeks. (Non-remission is defined as a score of moderate or high ( >2) on the Global Rating of Hallucinations in the scale for the assessment of positive symptoms (SAPS) 6. Capacity to consent for research studies as per the assessment using the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) 7. Ability to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Psychiatric emergency necessitating electroconvulsive therapy; 2. Suicidal risk / any psychiatric emergency; 3. Score of > 6 on Calgary Depression Rating Scale (Addington et al.,1994); 4. Pregnancy / Post-Partum; 5. substance use disorder in last six months (except caffeine ornicotine); 6. Co-morbid neurological / medical disease that can affect the brain structure / function. 7. Any Contraindication for Magnetic Resonance Imaging; 8. Any Contraindication for Transcranial Magnetic Stimulation. 9. Any Contraindication for Transcranial Direct Current Stimulation. 10. Hearing impairment 11. History of significant head injury (loss of consciousness more than30 minutes or any permanent sequelae)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the neuromodulatory effect of cTBS and tDCS (Neuromodulation) on ipseity encoding(measured by DIFFERENCE OF N100 amplitude between talk and listen condition) and source monitoring deficit(P300 amplitude measured during source monitoring task) in patients with persistent auditory hallucination with schizophrenia via specific event related potential(ERP) parametersTimepoint: The effect will be determined by assessing the ERP parameters at 2 time points: before neuromodulation treatment and after 15 days of neuromodulation treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To compare the ipseity monitoring ERPs in schizophrenia patients with medicationresistant persistent auditory hallucination with that of matched healthy control. 2. To compare the relative improvement of ipseity monitoring ERPs in schizophrenia patients with medication-resistant persistent auditory hallucination after cTBS TMS and tDCS intervention. 3.To evaluate the resting-state fMRI correlates of ipseity monitoring deficit and its change with NIBS intervention in patients of schizophrenia with medication-resistant persistent auditory hallucination. 4. To correlate the change in neurophysiological(ERPs) and neuroimaging (resting state fMRI) data evaluating ipseity monitoring deficit and itsimprovement with NIBS intervention with that of psychopathological variables assessing the severity of auditory hallucination in patients of schizophrenia with medication resistant persistent auditory hallucination.related potential studies.Timepoint: 2 time points: before intervention and after intervention | — |
Countries
India
Contacts
Public ContactDr Subham Samantaray
Central Institute of Psychiatry, Ranchi
Outcome results
None listed